Frost & Sullivan Lauds MEDRAD Excellent Product Innovation Abilities in the MRI Coils Market
16 Août 2006 - 5:50PM
PR Newswire (US)
PALO ALTO, Calif., Aug. 16 /PRNewswire/ -- Frost & Sullivan
selected MEDRAD, Inc. for its 2006 Product Differentiation
Innovation Award in recognition of its full line of eCoil(TM)
products. These products offer unprecedented MR imaging of pelvic
regions such as the prostate, colon, bladder, and cervix, to assist
physicians in cancer diagnosis, staging, and radiation therapy
planning. The eCoil product line has expanded to include the first
prostate endorectal coils for the fast-growing 3.0T scanner market.
The 3.0T Prostate eCoil joins disposable prostate, colorectal, and
cervix endorectal coils that are currently the main internal coils
for pelvic imaging for both 1.0T and 1.5T MR systems. These coils
offer significantly higher signal-to-noise ratios than traditional
pelvic coils as well as assist physicians in diagnosing tumor
stages of various cancers. Nearly all major MR scanner
manufacturers include MEDRAD's eCoils in their coil inventory. "The
predominant coil offerings from third-party manufacturers are
mainly head, neck, spine, breast, and extremity coils for knees,
wrists, and shoulders," says Frost & Sullivan Research Analyst
Subha B. Basu. "MEDRAD introduced endorectal coils in order to
effectively visualize the pelvis and lower abdomen structures
without the need for invasive surgical procedures such as
laparoscopy or endoscopies." MR-based diagnoses of pelvic and
endorectal examinations are especially important due to the
projected increase in prostate cancer incidence rates in males and
colorectal cancers in both males and females. According to data
from the American Cancer Institute, in 2005, the incidence of
prostate cancer in males is expected to be 33 percent, while
colorectal cancer is likely to occur in almost 11 percent of both
males and females. The number of deaths from prostate, colorectal,
and urinary bladder cancers is expected to top 70,000 among males
in 2005. However, the five-year survival rate for patients with
malignant tumors that have been detected early and localized to the
organ of origin is over 90 percent for colorectal, bladder,
cervical, and prostate cancers. The eCoils line of MR internal
coils from MEDRAD is helping lower fatalities attributed to
endorectal cancers. It also identifies physiological abnormalities
of the prostate and pelvic organs. This can help remedy
incontinence, erectile dysfunction, and neuromuscular dysfunction
of the lower abdomen and pelvis. "MEDRAD's position as a leading
provider of both surface and internal coils have consistently
helped increase company revenues, which exceeded $400 million in
2005," notes Basu. "In addition to eCoils, the company also has an
array of surface coils for multi-channel, phased array coils for
neurovascular, extremity, and torso imaging." Each year Frost &
Sullivan presents this Award to a company that has demonstrated the
ability to develop and/or advance products with more innovative
capabilities than competing vendors and products. The Award
recognizes the company's successful adoption of new or existing
technology that has become a part of its well-designed product
family. Such innovation is expected to significantly contribute to
the industry in terms of product performance and degree/rate of
technical change. Frost & Sullivan Best Practices Awards
recognize companies in a variety of regional and global markets for
demonstrating outstanding achievement and superior performance in
areas such as leadership, technological innovation, customer
service, and strategic product development. Industry analysts
compare market participants and measure performance through
in-depth interviews, analysis, and extensive secondary research in
order to identify best practices in the industry. About MEDRAD,
Inc. MEDRAD, Inc. is a global leading provider of medical devices
and services that enable and enhance imaging procedures of the
human body. Used in diagnostic imaging, MEDRAD's product offerings
include a comprehensive line of vascular injection systems,
magnetic resonance (MR) surface coils and patient care products, as
well as equipment services. MEDRAD, Inc. is the recipient of the
2003 Malcolm Baldrige National Quality Award, the top honor a U.S.
company can receive for quality and business excellence. The
company's world headquarters is near Pittsburgh, Pennsylvania, in
the United States. MEDRAD, Inc. is a U.S. affiliate of Schering AG,
Germany (NYSE:SHR). For more information visit the MEDRAD Website
at http://www.medrad.com/ . About Frost & Sullivan Frost &
Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies
for more than 40 years. The company's industry expertise integrates
growth consulting, growth partnership services, and corporate
management training to identify and develop opportunities. Frost
& Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics. For more information,
visit http://www.awards.frost.com/ or
http://www.medicalimaging.frost.com/ . Contact: Stacie Jones
210.247.2450 DATASOURCE: Frost & Sullivan CONTACT: Stacie Jones
of Frost & Sullivan, +1-210-247-2450, or Web site:
http://www.frost.com/ http://www.awards.frost.com/
http://www.medicalimaging.frost.com/ http://www.medrad.com/
Copyright
Schering Aktiengesel (NYSE:SHR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Schering Aktiengesel (NYSE:SHR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024